These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21856435)

  • 1. 11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension.
    Sacerdoti D; Jiang H; Gaiani S; McGiff JC; Gatta A; Bolognesi M
    Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):72-5. PubMed ID: 21856435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.
    Sacerdoti D; Gatta A; McGiff JC
    Prostaglandins Other Lipid Mediat; 2003 Oct; 72(1-2):51-71. PubMed ID: 14626496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats.
    Bolognesi M; Zampieri F; Di Pascoli M; Verardo A; Turato C; Calabrese F; Lunardi F; Pontisso P; Angeli P; Merkel C; Gatta A; Sacerdoti D
    Liver Int; 2011 Jul; 31(6):881-90. PubMed ID: 21645220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.
    Feng HQ; Weymouth ND; Rockey DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Jul; 297(1):G27-33. PubMed ID: 19299580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased sinusoidal resistance is responsible for the basal state and endothelin-induced venoconstriction in perfused cirrhotic rat liver.
    Shibamoto T; Kamikado C; Koyama S
    Pflugers Arch; 2008 Jun; 456(3):467-77. PubMed ID: 18193271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of epoxyeicosatrienoic acid production in rats with cirrhosis has beneficial effects on portal hypertension by reducing splanchnic vasodilation.
    Di Pascoli M; Zampieri F; Verardo A; Pesce P; Turato C; Angeli P; Sacerdoti D; Bolognesi M
    Hepatology; 2016 Sep; 64(3):923-30. PubMed ID: 27312119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin-induced vasoconstriction in isolated perfused liver preparations from normal and cirrhotic rats.
    Elliot AJ; Vo LT; Grossman VL; Bhathal PS; Grossman HJ
    J Gastroenterol Hepatol; 1997 Apr; 12(4):314-8. PubMed ID: 9195372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arachidonic acid metabolites and endothelial dysfunction of portal hypertension.
    Sacerdoti D; Pesce P; Di Pascoli M; Brocco S; Cecchetto L; Bolognesi M
    Prostaglandins Other Lipid Mediat; 2015 Jul; 120():80-90. PubMed ID: 26072731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
    J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
    Sakamoto M; Nakamura T; Torimura T; Iwamoto H; Masuda H; Koga H; Abe M; Hashimoto O; Ueno T; Sata M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):168-78. PubMed ID: 22849788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogen sulfide differentially affects the hepatic vasculature in response to phenylephrine and endothelin 1 during endotoxemia.
    Norris EJ; Larion S; Culberson CR; Clemens MG
    Shock; 2013 Feb; 39(2):168-75. PubMed ID: 23143058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
    Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
    Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function.
    Imig JD
    Prostaglandins Other Lipid Mediat; 2013; 104-105():2-7. PubMed ID: 23333581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis.
    Zhao X; Deng B; Xu XY; Yang SJ; Zhang T; Song YJ; Liu XT; Wang YQ; Cai DY
    World J Gastroenterol; 2013 Sep; 19(36):6069-76. PubMed ID: 24106408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance.
    Kojima H; Yamao J; Tsujimoto T; Uemura M; Takaya A; Fukui H
    J Hepatol; 2000 Jan; 32(1):43-50. PubMed ID: 10673066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in vascular reactivity of mesenteric arterioles in portal hypertensive and non-portal hypertensive rats.
    Zhang B; Ji LH; Zhang CG; Zhao G; Wu ZY
    World J Gastroenterol; 2019 Oct; 25(39):5953-5960. PubMed ID: 31660032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction.
    Moleda L; Trebicka J; Dietrich P; Gäbele E; Hellerbrand C; Straub RH; Sauerbruch T; Schoelmerich J; Wiest R
    Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
    Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
    World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.